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Abstract: 
The current thesis investigated a potential relationship between Alzheimer disease 
and type-2 diabetes mellitus by analysing early gene expression related to insulin 
receptor signalling in the hippocampus as well as glucose metabolism in APP/PS1 
mice, a model of familial Alzheimer disease. 
Compared to wild-type animals, a reduction in hippocampal insulin receptor and 
insulin-receptor substrate 2 transcripts in APP/PS1 mice three-month old as well as 
an increase in insulin-like growth factor 2 transcripts after six months was detected 
using real-time polymerase chain reaction. The alterations in hippocampal insulin 
signalling were accompanied by perturbation of glucose metabolism analysed by 
intraperitoneal glucose tolerance test. At the age of six months APP/PS1 mice 
developed glucose intolerance.  
Learning and recognition memory in APP/PS1 mice were tested using the Novel 
Object Recognition Test. Cognitive decline became evident in APP/PS1 mice at six 
months of age.  
Degradation of both insulin and amyloid β is mediated through insulin-degrading 
enzyme. However, expression of insulin-degrading enzyme in APP/PS1 mice was not 
different from wild-type littermates.  
Changes in hippocampal phosphorylation of the tau phosphoepitopes serine 199, 
threonine 205, serine 396 and serine 404 were investigated using Western blot. 
Levels of three phosphoepitopes were increased significantly at either age. 
 IV 
 
Protein expression of the phosphorylated form of glycogen synthase kinase 3β 
remained unchanged indicating an alternative pathway of tau phosphorylation in the 
APP/PS1 mouse model of familial Alzheimer disease.  
The current results demonstrate an increase in cyclin-dependant kinase 5 
phosphoralyted at tyrosine 15 in APP/PS1 mice at three and six months of age. The 
correlation between elevated levels of phosphorylated tau and cyclin-dependant 
kinase 5 suggests that cyclin-dependant kinase 5 might contribute to tau 
phosphorylation in APP/PS1 mice. 
In general, this work corroborates common pathologic features in Alzheimer disease 
and diabetes mellitus. A significant cognitive decline in APP/PS1 mice was 
associated with changes in early gene expression of insulin-related molecules and 
perturbations in glucose metabolism. Cyclin-dependant kinase 5 is considered to co-
regulate tau phosphorylation in APP/PS1 mice, and to be part of a pathway 
contributing to pathology in Alzheimer disease. 
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1 Introduction 
1.1 A brief introduction on Alzheimer disease and diabetes mellitus 
Alzheimer disease (AD) is the most common neurodegenerative disease in the 
elderly affecting more than 15 million people worldwide, mostly in highly 
developed countries. Due to higher life expectancy, as a consequence of high 
living-standard and the improvement of medical care the number of people 
affected with this form of dementia is supposed to quadruple by the year 2050 
(Luchsinger et al. 2005). According to the American Alzheimer Association 
there are more than five million AD patients in America making it the sixth 
leading cause of death. The current annual costs of 226 billion $ for AD and 
other dementias will rise to approximately 1.1 trillion $ in 2050 (http://www.alz. 
org/facts/overview.asp). In Germany around 1.2 million people are currently 
suffering from AD. 70 % are attended by family members. 
AD is characterized by cognitive deficits (Gilman 1997, Sims-Robinson et al. 
2010). Hallmarks of the disease are neurofibrillary tangles (NFT) composed of 
hyperphosphorylated tau as well as amyloid β (Aβ) in its soluble and 
aggregated form (Blennow et al. 2006, Li and Holscher 2007). However, about 
30 % of normal-aged individuals have a similar amount of Aβ plaques as AD 
patients (Iqbal et al. 2014). Obviously, both senile plaques and NFT are of 
multifactorial origin and not unique to AD. 
Also calcium homeostasis is affected in AD pathology as Aβ induces L-type 
voltage-sensitive calcium channels (LVSCC) that in conjunction with the over-
excitation of postsynaptic N-Methyl-D-aspartate receptors causes an excessive 
entry of calcium into the post-synaptic neurons eventually leading to neuronal 
death (Annweiler and Beauchet 2012). Moreover, in AD patients brain mass is 
decreased by about 5-fold compared to normal loss of 0.5 % of the brain mass 
per year. Impaired cell differentiation and regeneration due to developed AD 
pathologies mainly in the hippocampus result in rapid progression of 
neurodegeneration in AD patients (Iqbal et al. 2014). 
The rare (5-10%) early onset familial Alzheimer disease (FAD) is caused by 
mutations in amyloid precursor protein (APP) and presinilin (PS) 1 or PS 2, 
forming the catalytic core of γ-secretase (Sims-Robinson et al. 2010). The 
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cause of the common (90%) sporadic form of AD remains unknown. 
Nevertheless complex interaction of genetic and environmental risk factors are 
assumed to contribute to the evolvement of the disease that normally affects 
people aged older than 65 (Blennow et al. 2006, Li and Holscher 2007). 
Diabetes mellitus is a chronic metabolic disorder. Type-1 diabetes mellitus is 
caused by insufficient production of insulin by the pancreas. Type-2 diabetes 
mellitus (T2DM) patients develop peripheral insulin resistance. Uncontrolled 
diabetes leads to hyperglycaemia and irreversible damage to the nervous and 
blood systems. According to the World Health Organization currently about 347 
million people have diabetes worldwide. Death caused by diabetes will 
approximately double between 2005 and 2030 (http://www.who.int/diabetes/en/). 
1.2 Relationship between Alzheimer disease and diabetes mellitus 
AD is also characterized by the following risk factors: vascular lesions, 
hyperglycaemia, hyperinsulinaemia, insulin resistance, glucose intolerance, 
adiposity, atherosclerosis and hypertension that are also relevant for diabetes 
(Haan 2006). This strongly suggests that there might be a correlation between 
AD and diabetes mellitus and vice versa, which is underlined by multiple 
epidemiological studies (Haan 2006).  
Luchsinger et al. (2005) examined longitudinally the development of AD in 
1.138 individuals. They concluded that among several vascular risk factors, 
smoking and diabetes were strongest contributors to the development of AD. 
Another review examined the risk of dementia in diabetes mellitus in 14 
longitudinal population-based studies (Biessels et al. 2006). The incidence of 
any type of dementia was increased in individuals with diabetes in two out of 
three studies, in which midlife diabetes was assessed 25-30 years before the 
actual follow up study. In general Biessels et al. (2006) suggests that alterations 
in insulin and glucose signalling as well as amyloid metabolism contribute to AD. 
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1.2.1 Major pathways of insulin signalling 
Binding of insulin to the insulin receptor (IR) results in activation and 
autophosphorylation of the receptor tyrosine kinase. Insulin receptor substrate 
(IRS) is phosphorylated and activated. Phosphorylation of IR and/or IRS 
activate mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) 
signalling pathway (De La Monte and Wands 2008).  
Akt signalling pathway, related to cell growth, cell proliferation and protein 
synthesis inhibits glycogen synthase kinase (GSK) 3β that inactivates glycogen 
synthase, a key enzyme in glycogenesis (Figure 1). 
 
Figure 1: Insulin signalling in diabetes and Alzheimer disease pathophysiology. In type-1 
diabetes, insulin deficiency attenuates long-term potentiation (LTP) and might lead to deficits in 
spatial learning and memory. In type-2 diabetes, insulin resistance leads to both amyloid β (Aβ) 
plaque formation and tau hyperphosphorylation. During hyperinsulinaemia, insulin and amyloid 
β compete for insulin-degrading enzyme, leading to amyloid β accumulation and plaque 
formation. A decrease in insulin receptor signalling leads to inhibition of Akt and 
dephosphorylation (activation) of glycogen synthase kinase 3β (GSK-3β), and results in tau 
hyperphosphorylation (Sims-Robinson et al. 2010). 
Functional IR signalling might induce GSK3β inactivation. On the contrary, 
dysfunction of IR signalling provoking insulin resistance leads to 
dephosphorlylation of GSK3β and its activation. Thus in insulin-resistant 
individuals, such as T2DM patients there is an increase in GSK3β activity due to 
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glucose clearance (Lee and Kim 2007). Interestingly, primary cultured 
hippocampal neurons with mutation in PS1 have an increased GSK3β activity. 
Down-regulation of Akt leads to higher production of Aβ and NFT (Balaraman et 
al. 2006). 
As can be seen in Figure 1 insulin receptor-dependent activation of GSK3β 
might play a key role in developing the two hallmarks of AD, senile Aβ plaques 
and NFT consisting of hyperphosphorylated tau (Balaraman et al. 2006). 
According to Munoz and Ammit (2010) the MAPK signalling pathway 
contributes in different ways to the pathological feature of AD. Besides 
neuroinflammatory effects, MAPKs pathway might be associated with 
excitotoxicity, synaptic plasticity and phosphorylation of tau. The stress-
activated enzyme p38 MAPK subfamily capable of inducing apoptosis can be 
found in increased levels in AD brains compared to age-matched normal brains. 
Moreover in AD brains, increased phospho-p38-immunoreactivity correlated 
with high incidence of senile Aβ plaques and NFT (Hensley 1999, Sims-
Robinson et al. 2010). 
Zhang et al. (2012) investigated IR signalling in the liver of APP/PS1 mice. 
APP/PS1 mice killed five minutes after insulin injection did not show a 
physiological increase in IR density compared to wild-type (WT) littermates 
(Figure 2). 
 
Figure 2: insulin receptor-signalling in the liver of APP/PS1 mice compared to WT. Experiments 
performed by Zhang et al. (2012). 
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1.2.2 Amyloid β oligomers, amyloid β processing and insulin signalling 
Insulin signalling is supposed to play a key role in the development of diabetes 
and AD. Over 30 years ago it was published that in addition to periphery IR, 
expression was also found in different areas of the rat brain mostly connected to 
food intake, such as the hypothalamus. The concentration of insulin in the brain 
was found to be about 10-fold higher than in the blood. Expression of IR in the 
brain was not influenced by peripheral changes e.g. in the liver (Havrankova et 
al. 1981). According to Steen et al. (2005) levels of IRS and its associated 
phosphatidylinositol 3-kinase (PI3K) were reduced significantly in AD brains. At 
the same time increased activation of GSK3β and APP was found. Based on 
these results they referred to AD as "diabetes type 3". In 2004, Watson and 
Craft published a review about insulin and glucose and their effects on memory 
formation in AD brains. They pointed out that AD patients often have an 
impaired glucose regulation and AD worsens already existing pathologic insulin 
changes.  
β-secretase and γ-secretase generate Aβ by proteolysis of APP. The 42 amino 
acid form of the peptide aggregates easily and forms extracellular senile 
plaques. Aβ deposits might influence synaptic function and lead to apoptosis of 
neuronal cells (Sims-Robinson et al. 2010)  
Evidently next to the aggregated plaques soluble highly toxic and dangerous Aβ 
oligomers exist (Klein 2013). According to Lacor et al. (2004) Aβ oligomers are 
connected to early memory loss by blocking long-term potentiation (LTP).  
In 2008, Zhao et al. investigated the influence of Aβ oligomers on IR in the brain. 
Aβ oligomers bind synaptic IR, block them and suppress insulin signalling. In 
response, the level of Akt phosphorylated at serine 473 increased (Zhao et al. 
2008). 
Phosphorylation of IRS 1 on tyrosine is required for normal insulin-response, 
the phosphorylation of IRS 1 on serine either enhances or terminates the insulin 
effects (Gual et al. 2005). According to Bomfirm et al. (2012) elevated levels of 
phosphorylation on serine residues of IRS 1 might be a link between diabetes 
and AD. Aβ oligomers increase serine phosphorylation of IRS 1 by inducing C-
Jun N-terminal kinases/tumour-necrosis factor α pathway (Bomfirm et al. 2012, 
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Klein 2013). Consequently, Aβ oligomers might induce insulin resistance 
leading to hyperinsulinaemia which can be often found together with the 
manifestation of senile plaques and impaired cognitive function (Klein 2013). 
Insulin and Aβ both compete for the binding site of insulin-degrading enzyme 
(IDE, see Figure 1) for decomposition. High levels of insulin in T2DM might 
consequently lead to Aβ accumulation (Gasparini and Xu 2003). Due to 
decreased density of IR in AD patients insulin sensitizers may be a useful 
therapy. They could prevent Aβ accumulation by decreasing competitive levels 
of insulin in the brain (Pedersen et al. 2006). 
1.2.3  Insulin, insulin-like growth factor 1 and tau phosphorylation 
Tau is a protein that supports stabilizing the microtubule structure in neuronal 
cells. It is indicated that insulin and insulin-like growth factor (IGF) 1 might 
influence the development of NFT consisting of hyperphosphorylated tau. 
Hyperphosphorylated tau can be found in higher levels in foetal brains, where it 
down regulates the stability of the tubulus structure. Neuronal plasticity is thus 
established (Gasparini and Xu 2003). In the same study it is assumed that 
insulin could be a regulator of tau phosphorylation and increases the 
aggregation of hyperphosphorylated tau into NFT. 
In 2003, Schubert et al. investigated whether there is an increase of tau 
phosphorylation in IRS 2 knockout mice. Phosphorylation of tau 
phosphoepitope serine 202 connected to NFT formation was increased 
significantly in extracts of IRS 2 double knockout mice at six weeks of age 
(Schubert et al. 2003). De Felice et al. (2008) addressed the question whether 
Aβ oligomers itself influence hyperphosphorylation of tau. They showed that 
next to synthetic soluble Aβ oligomers also Aβ oligomer-containing soluble 
extracts from AD brains increase tau hyperphosphorylation. Also more recent 
studies underline the detrimental effect of Aβ oligomer-induced tau 
phosphorylation on the tubulus structure resulting in loss of axonal transport 
and synaptic decomposition (Zempel and Mandelkow 2012). 
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1.3  Role of cholesterol and apolipoprotein E in diabetes and Alzheimer 
disease 
Hypercholesterolemia is suggested to be a risk factor for AD and diabetes. 
Apolipoprotein E (APO E) responsible for the transport of cholesterol and 
lipoproteins in the blood has a large influence on blood lipid levels. APO E 
deficiency leads to higher levels of blood cholesterol, underlined by APO E 
knockout mice, fed with low fat diet, showing increased blood cholesterol levels 
compared with the WT control group. The most common allele of APO E is APO 
E ε3 normally expressed in more than 70% of the population, only 15% 
expressing APO E ε4. APO E ε4 increases individual risk for developing AD by 
3-4-fold. 40% of AD patients have the APO E ε4 allele. Diabetic patients 
possessing the APO E ε4 allele are twice as likely to develop AD than non-
diabetic individuals also bearing APO E ε4 (Sims-Robinson et al. 2010). 
According to Small et al. (2000) carriers of APO E ε4 who developed AD have 
lowered parietal, temporal and posterior cingulate glucose levels, leading to 
significant cognitive impairment after two years of longitudinal follow up. 
Apparently APO E ε4 might also be involved in Aβ clearance and tau 
phosphorylation. APO E ε4 aggregated fragments that cause NFT-like 
inclusions can be found in cultured neuronal cells as well as in APO E ε4 
transgenic mice (Brecht et al. 2004). 
According to Harris (1991) 70% of T2DM patients have hypercholesterolemia 
leading to reduced insulin secretion due to accumulation of cholesterol in 
pancreatic β cells. Referring to Sharma et al. (2008) the cholesterol metabolite 
27-hydroxycholesterol, that is able to cross the blood brain barrier, possibly 
induces high levels of Aβ in AD patients. Rabbits fed with high-cholesterol diet 
showed elevated levels of Aβ in the hippocampus accompanied by reduced 
IGF-levels, a growth factor that regulates GSK3α and IDE. 
2 Aim of work 
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2 Aim of work 
The current thesis investigated whether the development of familial Alzheimer 
disease in the APP/PS1 mouse model might be associated with glucose intolerance 
and alterations in hippocampal insulin signalling. 
The APP/PS1 transgenic mouse model of familial AD was used as model to mimic 
human AD pathology. This model is characterized by a significant overexpression of 
APP/PS1 in the hippocampus of three- and six-month old animals.  
The current work investigated whether tau phosphorylation as a hallmark of AD may 
be linked to metabolic routes related to glucose uptake and insulin signalling. 
The MAPKs cyclin-dependant kinase 5 and GSK3β are considered to be major tau-
kinases in the brain. Thus it was investigated whether one is more important than the 
other in the APP/PS1 mice by using Western blot (WB) and real-time polymerase 
chain reaction (RT-PCR).  
With regard to the demonstrated impaired peripheral IR signalling (Zhang et al. 2012), 
the present work investigated whether the physiological IR signalling is affected also 
in the brain of the APP/PS1 mice by focussing on mRNA and protein expression of 
preproinsulin, IR, IRS 1, IRS 2, IGF 1 and IGF 2 in the hippocampus of the APP/PS1 
mouse model compared to its WT littermates.  
IDE could be a key enzyme for linking AD with diabetes. Hence, potential changes in 
IDE in APP/PS1 mouse hippocampus were investigated 
Using the intraperitoneal glucose tolerance test (IP-GTT) development of glucose 
intolerance prior to development of insulin resistance, a hallmark of diabetes, was 
investigated.  
3 Methods 
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3 Methods 
3.1 A mouse model on early-onset Alzheimer disease: APP/PS1-transgenic   
mice 
The description below refers directly to the information provided by the "Jackson 
Laboratory" distributing the mouse model B6C3-Tg (APPswe,PSEN1dE9) 
85Dbo/Mmjax: (http://jaxmice.jax.org/strain/004462.html) used for the present study. 
In this double-transgenic mouse model, two mutations connected to early-onset AD 
and controlled by independent mouse prion protein promoter elements are 
introduced and the expression of the corresponding proteins is directed mostly to the 
brain: a human APP mutation (Mo/HuAPP695swe) resulting in secretion of a human 
Aβ peptide mostly through β-secretase pathway and a mutation in human PS1 (PS1-
dE9). Senile plaques consisting of Aβ deposits are reported at six to seven months of 
age (Figure 3). 
Animals were kept under controlled temperature, humidity and light conditions with 
food and water provided ad libitum. Mice were treated in accordance with the 
European Community Council Directive 86/609/EEC. Every effort was made to 
minimize animal suffering and to reduce the number of animals used.  
Figure 4 shows a result of a RT-PCR that was made as control of the quality and 
validity of transgene expression. Expression of APP can be found significantly higher 
in the APP/PS1 group compared to WT group. 
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Figure 3: Immunohistochemistry (mouse anti-human β-amyloid clone 6F/3D primary 
antibody 1:100; DakoCytomation, Denmark) of hippocampal tissue of APP/PS1 and wild-
type mice of three and six months of age showing development of amyloid β plaques 
(marked by arrow) in APP/PS1 mice at six months of age. Picture was kindly provided by 
Prof. Antonio Camins, Universitat de Barcelona. 
 
Figure 4: Real-time polymerase chain reaction of amyloid precursor protein mRNA 
expression in APP/PS1 mouse hippocampus of three and six months old animals. Significant 
increase in APP/PS1 mice at three (P<0,01 and six (P<0,001) months compared to age-
matched wild-type control group; open columns: wild-type animals; solid columns: APP/PS1 
mice; Means ± SEM are given; Tukey's post-hoc test **p˂0.01; ***p˂=0.001; n=4 
3 Methods 
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3.2 Novel Object Recognition Test 
Novel Object Recognition Test was used to evaluate recognition memory in the 
APP/PS1 mouse model as described by Barroso et al. (2013).  
In brief: the test was performed in a black-coloured 90º two arm maze (25 cm × 5 cm 
× 20 cm; see Figure 5) illuminated from above. In the middle of the field the light 
intensity was 30 lux. Plastic figures were chosen as objects to be discriminated 
(object A 5.25 cm high, object B 4.75 cm high). Between the trials objects, surface 
and maze were disinfected with 96% ethanol to remove olfactory cues. Mice were 
accustomed to experimental condition for two days in one 10-min session every day 
in the empty maze. The third day each animal performed a 10-min trial (first trial) in 
the presence of two identical objects (A + A or B + B) placed at the end of each arm. 
After a two-hour break mice were placed another ten minutes in the maze being 
confronted with the familiar object and a new object (A + B or B + A). During this 
second trial the time that the animal took to explore the new object (tn) and the old 
object (to) were recorded. A discrimination index (DI) was deﬁned as (tn−to) / (tn + to). 
In order to avoid object preference biases, objects A and B were counterbalanced so 
that half of the animals in each experimental group were ﬁrst exposed to object A and 
then to object B, whereas the other half saw ﬁrst object B and then object A.  
 
Figure 5: Sketch of black-coloured 90° two arm maze 
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3.3  Intraperitoneal glucose tolerance test  
With the intraperitoneal glucose tolerance test (IP-GTT) the clearance of 
intraperitoneally injected glucose was measured in order to find changes in glucose 
metabolism that can be linked to diabetic conditions. 
Materials and reagents: 
70% ethanol, Sigma D (+)-glucose solution (45%) (LOT RNBB9954) 
Equipment: 
BAYER Ascensia ELITE blood glucose meter (SN 9219685), BAYER ELITE blood 
glucose strips 3921 C (CAT#269571.9) 
IP-GTTs were performed at the department of pharmacology at the University of 
Barcelona in accordance to previously published guideline of Ayala et al. 2010.   
In brief: Before the day of procedure, cages and water supply were changed and 
animals were fasted for 14-16 hours. In the morning of the experiment the mice were 
moved to a quiet, temperature-controlled area with 28-30°C ambient temperature and 
were allowed to acclimate for 1-2 hours. The tip of the tail was cut with heparin-
soaked (5000 IU/ml; Laboratorios farmaceuticos ROVI, S.A.) sterile scissors and 
massaged carefully to take sufficient amount of peripheral blood. Basal glucose value 
was taken immediately after cutting the tail. Blood glucose measurements were taken 
at -30, 0, 5, 15, 30, 60 and 120 minutes following intraperitoneal glucose injection  
(1 g/kg body weight of 20% glucose solution, diluted with sterile water) with the 
Ascensia ELITE blood glucose meter. Injection was performed abdominally at a 30-
45 ° angle in the left side of the ventral axis in order to avoid puncturing the liver. 
3.4 Enzyme-linked-immunosorbent-assay  
The Mouse Insulin 96 Well Plate Assay was done with standardized procedure 
recommended by Millipore (http://www.millipore.com/userguides/tech1/proto_ezrmi-
13k). 
The sandwich enzyme-linked-immunosorbent-assay (ELISA) is used for non-
radioactive quantification of insulin in mouse and rat sera using quantification of 
immobilized antibody-enzyme conjugates by monitoring horseradish-peroxidase 
activity. 
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Reagents and Equipment: 
Rat/mouse insulin ELISA 96-well plate kit (Cat #: EZRMI-13K; EMD Millipore; St. 
Charles, MO, USA) 
In brief: Heart puncture was used to collect whole blood samples from three and six 
months-old WT and APP/PS1 mice, following a 5-hour morning fast, at the point of 
sacrifice. Blood samples were transferred to Serum-Gel Z microcentrifuge tubes 
(Sarstedt, Numbrecht, Germany), for serum separation. The samples were collected 
and kept at room temperature, and the serum was separated by centrifugation for 10 
min at 5000 x g.  
Serum insulin levels were measured with insulin ELISA, according to manufacturer’s 
instructions, utilizing 10 µl of mouse serum:  
All reagents were pre-warmed to room temperature prior setting up the assay. 10X 
wash buffer (WABU) concentrate was diluted 10 fold filling up each bottle of WABU 
with 450 ml de-ionized water. Required numbers of strips were removed from 
microtiter assay plate. Strips were kept in empty plate holder. Each well was washed 
3 times with 300 µl of diluted WABU per wash. Turning the plate and tapping it 
carefully onto absorbent towels removed the WABU. Important was to proceed 
before wells dried. 10 µl of assay buffer were added to each of the sample wells and 
the non-specific-binding wells (NSB). Afterwards 10 µl of matrix solution were added 
to the NSB, standard and control wells. Then 10 µl of rat insulin standards were 
added in duplicates in order of ascending concentration to appropriate wells. 10 µl of 
quality control 1 and 10 µl of quality control 2 were added to appropriate wells. Now 
10 µl of unknown samples were added in duplicates to the remaining wells. Within 
one hour 80 µl of detection antibody were added to the wells. After that the plate was 
covered with plate sealer and then incubated at room temperature for two hours 
rotating at 400 rpm on microtiter plate shaker. Plate sealer was removed and 
solutions were decanted from the plate, again tapping on absorbent towels. Wells 
were washed three times using 300 µl diluted WABU per wash. WABU was decanted 
using same procedure as before. Thereafter 100 µl of enzyme solution were added to 
each well. Afterwards the plate was covered with the sealer and incubated on the 
microtiter shaker at 400 rpm for 30 min. Shortly after this the sealer was removed and 
solution was decanted. Plate was turned and tapped on absorbent towels again. 
Wells were washed again six times using 300 µl of WABU per wash. Residual buffer 
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was decanted again. 100 µl of substrate solution were added to each well. Then the 
plate was covered with sealer and shaken for about 10 min on shaker at 400 rpm. 
Blue colour was formed in wells of insulin standards with proportional intensity 
increasing with insulin concentration. Sealer was removed and 100 µl of stop solution 
were added. Plate was shaken by hand. The blue colour turned yellow. Immediately 
absorbance was read at 450 nm and 590 nm in plate reader. 
3.5  Western blot 
The Western blot was used as an experimental technique to show protein expression 
and its changes in homogenate tissue and cell extracts. 
Materials and Reagents: 
Acrylamide solution (AppliChem A4983), TRIS-BASE (SIGMA LIFE Science T6066), 
Glycine Molecular biology grade (AppliChem A1067), Sodium chloride (AppliChem 
A1149), Sodium dodecyl sulfate (SDS, AppliChem A2572), 2-Mercapto ethanol 
(Sigma M3148), Bromophenol blue (Sigma B-8026), Isopropanol (AppliChem A3465)  
Equipment: 
BIO RAD Mini Protean® 3 System Glass Plates (Cat# 1653312), BIO RAD Mini 
Protean® Tetra Cell (SN 552BR), BIO RAD 15 well comb, BIO RAD Power Pack 200 
(SN 285 BR), Bio Rad Molecular Imager Chemi Doc TM XRS+ 
In brief: 
1 Determination of protein concentration 
Table 1: Standard curve preparation 
 
+ 1ml working reagent (24.5ml solution A + 0.5ml solution B --> 98%A-2%B) at same time as for 
samples 
The standard curve was prepared according to table 1. Starting by preparing the 80 
µg/ml in an Eppendorf tube and diluted as shown. Next total volume of working 
reaction needed was prepared. 2 µl of hippocampus sample and 48 µl of sterile water 
were put in an Eppendorf tube. Afterwards the working reagent was added at the 
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same time to the tubes with the standard curve and the samples. The next step was 
to place them quickly in a hot water bath at 60°C for 30 min. Duplicates of 100 µl 
were pipetted in a 96x well plate. Then absorbance was measured at 562 nm. 
1.1  Sample preparation 
Aliquots of hippocampus homogenate containing 15 mg of protein per sample were 
placed in a sample buffer (0.5 m TRIS–HCl, pH 6.8, 10% glycerol, 2% (w/v) SDS, 5% 
(v/v) 2-mercaptoethanol, 0.05% bromophenol blue) and denatured by boiling at 95–
100ºC for 5 min. 
Table 2: Sample buffer 2X 
TRIS-HCL 1M ph 6.8 625 µl 
SDS 10% 2 µl 
Glycerol 1 ml 
Β-Mercaptoethanol 0.5 ml 
Sterile water 274 µl 
Blau-bromophenol 
(0.1%) 
600 µl 
2  Electrophoresis 
2.1  Preparation of the polyacrylamid gel 
Table 3: Components of stacking and resolving gel 
 10% Resolving gel 5% Stacking gel 
Acrylamide 5.26 ml 700 µl 
TRIS-HCL (pH 8.8 
or 6.8) 
(8.8) 5.25 ml (6.8) 1.4 ml 
H2O 9.85 ml 3.6 ml 
SDS 10% 420 µl 120 µl 
APS 300 µl 60 µl 
TEMED 50 µl 10 µl 
Table 4: TRIS-HCL pH 8.8 1.5M 
TRIS-BASE 18.17 g  
H2O 100 ml 
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Table 5: TRIS-HCl pH 6.8 1M 
TRIS-BASE 12.1 g 
H2O 100 ml 
Table 6: SDS 10% 
SDS 10 g 
H2O 100 ml 
Preparation was started with the resolving gel. After adding the ammonium persulfate 
(APS), solution was carefully mixed before tetramethylethylenediamine (TEMED®) 
was added. Solution was mixed immediately and filled between the prepared glass 
plates so it could form the bottom layer. On top of the 10% resolving layer 
isopropanol was added. After the resolving gel was solid isopropanol was removed. 
Afterwards the 5% stacking gel was prepared. Stacking gel was added on top of the 
solid resolving gel and a comb for a 15-well gel was adjusted immediately. Once solid 
the comb was removed in running buffer that consisted of 900 ml distilled water and 
100 ml running buffer 10X.  
Table 7: Running buffer 10X 
Distilled water 1 l 
TRIS-BASE 30 g 
Glycine 144 g 
SDS 10 g 
2.2 Running the gel 
The gel was run at constantly 100 V for about 90-120 min. Because proteins were 
covered in negatively charged SDS they moved to the positively charged electrode. 
Smaller proteins migrated faster through the pores of the gel than bigger proteins, 
hence the proteins were separated by molecular weight. 
3 Transfer of protein 
Proteins were transferred to polyvinylidenfluorid sheets (0,20 µM pore) using 
transblot apparatus. Depending on the weight of the protein they were either 
transferred with constant 35 V overnight or constant 200 mA for 90 minutes in 
transfer buffer (700 ml of water, 200 ml of methanol, 100 ml of transfer buffer 10X). 
For proteins with a low molecular weight transfer within 90 min was preferred. After 
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the transfer, the membranes were washed three times for five minutes in TBS-T 
buffer (50 mM TRIS; 1.5% NaCl, 0.05% Tween 20, pH 7.5). 
Table 8: Transfer buffer 10X 
H2O 1l 
NaCl 80 g 
TRIS-BASE 24.25 g 
4 Blocking of membranes 
Membranes were blocked overnight with 5% non-fat milk dissolved in TBS-T buffer 
(50 mM TRIS; 1.5% NaCl, 0.05% Tween 20, pH 7.5). 
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5 Primary and secondary antibodies 
Table 9: Antibodies 
Antibody Manufacturer Primary 
antibody 
dilution 
Secondary 
antibody 
Predicted 
molecular 
weight 
Anti-insulin-
receptor 
Abcam 
Ab69508 
1:1000 Mouse 95 kDa 
IDE-antibody Abcam 
Ab32216 
1:1000 Rabbit 118 kDa 
GSK3β Cell signalling 
Technology 
#9315 
1:1000 Rabbit 46 kDA 
Phospho-GSK3β 
(Ser9) antibody 
Cell signalling 
Technology 
#9336 
1:1000 Rabbit 46 kDa 
CDK5 (C-8) Santa Cruz 
Biotechnology 
sc-173 
1:200 Rabbit 33 kDA 
Anti-CDK5 
(phospho Y15) 
Abcam ab63550 1:500-1:1000 Rabbit 33 kDA 
Tau Biosource 
#AHB0042 
1:1000 Mouse 4 bands 
44-60 kDA 
Anti-Tau (pS396) Invitrogen 
#44752G 
1:1000 Rabbit 65 kDA 
Anti-Tau (pS199) Invitrogen 
#44734G 
1:1000 Rabbit 65 kDA 
Anti-Tau (pT205) Invitrogen 
#44738G 
1:1000 Rabbit 65 kDA 
Anti-Tau (pS404) Invitrogen 
#44-758G 
1:1000 Rabbit 65 kDA 
GAPDH Millipore 
#MAB374 
1:500 Mouse 38 kDA 
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For Western Blot the membrane was incubated with antibody diluted in 5% bovine 
serum albumin in TBS-T buffer with gentle shaking overnight and incubated for 1 h 
with a peroxidase-conjugated immunoglobulin G secondary antibody (1:2000). In 
between primary and secondary antibody membrane was washed three times for five 
minutes in TBS-T buffer. 
6 Fluorescent detection 
Immunoreactive protein was detected using a chemiluminescence-based detection 
kit. Protein levels were determined by densitometry using Chemi doc XRS+ 
Molecular Imager detection system (Bio-Rad) with ImageLab image analysis software. 
Measurements are expressed as arbitrary units. All results are normalized to 
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH), unless stated otherwise. 
3.6 Real-time polymerase chain reaction 
The RT-PCR was used to amplify specific DNA molecules and to analyse its quantity 
while the reaction was in progress. 
RNA extraction and quantification: 
Total RNA was isolated from the hippocampi of WT and APP/PS1 transgenic mice, 
as described previously (Chomczynski and Sacchi, 1987).  
Briefly, the tissue was homogenized in the presence of TRIzol reagent (Life 
Technologies Corporation, TRIzol® Reagent Cat. # 15596). Chloroform was added 
and the RNA was precipitated from the aqueous phase with isopropanol at 4ºC. RNA 
pellet was reconstituted in RNase-free water, with the RNA integrity determined by 
Agilent 2100 Bioanalyzer. 
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Materials and reagents: 
TaqMan® Gene Expression Master mix (MM) (Applied Biosystems Ref:4369016) 
Table 10: Primers and probes used for RT-PCR 
Primer TaqMAN Probe 
INS 1 Ins1-Mm01950294_s1 
IR IR-Mm01211875_m1 
IRS 1 Irs1-Mm01278327_m1 
IRS 2  Irs2-Mm03038438_m1 
IDE Ide-Mm00473077_m1 
IGF 1 Mm01228180_m1 
IGF 2 Mm00439561_m1 
GSK3β Gsk3b-Mm00444911_m1 
Equipment: 
Applied Biosystems step one plus RT-PCR systems (SN: 272005541), 
Applied Biosystems Optical Adhesive Covers (CAT#4360954), 
Applied Biosystems Micro Amp Fast 96 – Well Reaction Plate (0.1ml)(CAT#4346907) 
In brief: 
 
 
Hippocampus cDNA samples at 2 ng/µl RNA equivalent were defrosted completely. 
Then cDNA and MM were mixed at equal amounts. 1.5 µl of probe mix (0.25 µl probe 
+1.25 µl sterile water) was pipetted in each well of the plate. 1.5 µl of MM + cDNA 
were added. Optical adhesive cover was put on top of the plate. Plate was 
centrifuged for 2 min at 500 x g/min. Plate was run at manufacturer recommended 
condition. 
 
1.5 µl probe (0.25 µl probe +1.25µl H2O) 
13.5 µl MM + cDNA 
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3.7 Statistical analysis  
All data are presented as means ± SEM, and differences are considered significant at 
p<0.05, p<0.01 and p<0.001. Differences between samples/animals were evaluated 
using either one-way ANOVA, with Tukey's post-hoc test, where * denotes p<0.05, ** 
denotes p<0.01, *** denotes p<0.001 and with the student's t-test, where $ denotes 
p<0.05, $$ denotes p<0.01 and $$$ denotes p<0.001. Both the statistical analyses 
and the graphs presented here were created with the GraphPad InStat software V 
5.0 (GraphPad Sofware Inc., San Diego, CA, USA). 
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4 Results 
4.1 Glucose levels during glucose tolerance test in APP/PS1 and wild-type 
mice 
Blood glucose levels after intraperitoneal injection (1.0 g/kg) were significantly 
different between APP/PS1 mice and WT littermates. During the acute phase of the 
glucose tolerance test (15-60 min after glucose injection), glucose levels of APP/PS1 
mice were elevated in both young and old ages. The amplitude of changes in glucose 
levels from baseline was significantly elevated in APP/PS1 animals at six months of 
age (to about 300 mg/dl). The peak level of glucose in this group remained 
significantly above physiological levels for the whole observation period of 120 min. 
As indicated also young APP/PS1 mice showed higher glucose levels than WT 
littermates up to 60 min after glucose injection, nevertheless its level gradually 
decreased to the physiological baseline level at 120 min. Glucose levels of young 
and older WT mice were comparable after glucose loading at all measure points. 
These results demonstrate the difference between the genotypes. Most interestingly 
in older APP/PS1 mice glucose levels did not decrease to physiological baseline 
levels suggesting the development of glucose intolerance (Figures 6 A-C).  
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Figure 6: Glucose curves of APP/PS1 mice of three months (A), six months of age (B), and 
corresponding area under the curve (AUC C) compared to wild-type (WT) littermates. 
Determinations were made using intraperitoneal glucose tolerance test (IP-GTT) according 
to previously described guidelines (see method section); open columns: wild-type animals; 
solid columns: APP/PS1 mice. Means ± SEM are given; Student's t-test $ p<0.05; n= 4-11; 
M month 
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4.2 Changes in serum insulin levels related to age 
The increase in insulin serum levels correlating with the age of the mice did not reach 
statistical significance (pWT = 0.1576, pAPP = 0.2547). In six months old mice 
concentration of insulin was up to two folds higher than in three months old animals 
(Figure 7).  
 
Figure 7: Serum insulin levels in APP/PS1 mice three and six months old. Determinations 
were made by enzyme-linked-immunosorbent-assay according to previously described 
guidelines (see method section); open columns: wild-type (WT) animals; solid columns: 
APP/PS1 mice. Means ± SEM are given; n=4-6; M month 
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4.3 Changes in gene expression related to insulin receptor signalling in three- 
and six-month old APP/PS1 transgenic mice  
Insulin is the key enzyme regulating glucose metabolism. The mechanism of 
endogenous production in the brain remains mostly unknown. Levels of preproinsulin, 
IR, IRS 1, IRS 2 as well as IGF 1 and 2 in mouse hippocampus of APP/PS1 mice and 
WT control group were investigated. Although no changes in levels of insulin, IRS 1 
and the IGF 1 receptor were found, a significant decrease (p˂0.05) in IR expression 
and levels of IRS 2 in young APP/PS1 littermates (three months) was observed. 
Moreover a significant increase (p˂0.05) in mRNA expression of IGF 2 at six months 
of age was detected (Figure 8 A-F). 
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Figure 8: mRNA expression of preproinsulin (A), insulin receptor (B), insulin-receptor 
substrate 1 (C), insulin-receptor substrate 2 (D), insulin-like growth factor 1 (E) and insulin-
like growth factor 2 (F) in hippocampus of APP/PS1 mice at three and six months of age. 
Real-time polymerase chain reaction was performed according to standard protocol (see 
method section); open columns: wild-type (WT) animals; solid columns: APP/PS1 mice. 
Means ± SEM are given; Tukey's post-hoc test *p˂0.05; n=4-6; M month  
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4.4 Protein expression and mRNA expression of insulin-degrading enzyme 
did not change in APP/PS1 mice 
An increase or decrease in IDE could not be found in APP/PS1 mice. Protein 
expression and mRNA expression did not change significantly in this specific mouse 
model (Figure 9 A-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: mRNA expression (A) and protein expression of insulin-degrading enzyme in 
hippocampus of three months (B) and six months (C) old APP/PS1 mice. Western blot and 
real-time polymerase chain reaction were performed according to standard protocol (see 
method section). Open columns: wild-type (WT) animals; solid columns: APP/PS1 mice. 
Means ± SEM are given; n 4-6; M month; GAPDH Glycerinaldehyd-3-phosphat-
dehydrogenase 
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4.5 Protein expression of cyclin-dependant kinase 5 increases in APP/PS1 
mouse hippocampus at three and six months of age 
Cyclin-dependant kinase 5 (CDK5) is a serine threonine kinase that forms complexes 
with p35 or p39. It is expressed in neurons and pancreatic β-cells. In addition to its 
role as a major tau-kinase, it is suggested to be an upstream signalling molecule 
regulating glucose-stimulated insulin secretion in the pancreas (Ahmed and Sharma 
2011). Thus it could be a key enzyme linking AD and diabetes. A significant increase 
in CDK5 phosphorylated at tyrosine 15 (Y15) was observed in APP/PS1 compared to 
WT mice at three (p ˂ 0.05) and six months (p˂ 0.01) of age (Figure 10 A and B) 
 
 
 
 
 
 
Figure 10: Protein expression of cyclin-dependant kinase 5 phosphorylated on tyrosine 15 
(pCDK5 Y15) in hippocampus of three months (A) and six months (B) old APP/PS1 mice. 
pCDK5 Y15 is normalized to its respective total unphosphorylated protein level and 
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH). Western blot was performed 
according to standard protocol (see method section). Open columns: wild-type (WT) animals; 
solid columns: APP/PS1 mice. Means ± SEM are given, Student's t-test $ p< 0.05, $$ p< 
0.01; n=4-6; M month  
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4.6 Levels of glycogen synthase kinase 3β maintain constant in Western blot 
and real-time polymerase chain reaction analysis 
GSK3β is a kinase downstream of the IR. As described before it is also a 
downstream target of Akt and may play a significant role in tau-signalling. Studying 
the phosphorylation on serine 9 using WB and RT-PCR no significant changes were 
found comparing APP/PS1 mice with their WT littermates (Figure 11 A-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: mRNA expression (A) and protein expression of glycogen synthase kinase 3β 
phosphorylated on serine 9 (pGSK3β S9) in hippocampus of three-month (B) and six-month 
(C) old APP/PS1 mice. pGSK3β S9 is normalized to its respective total unphosphorylated 
protein level and glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH). Western blot was 
performed according to standard protocol (see method section). Open columns: wild-type 
(WT) animals; solid columns: APP/PS1 mice. Means ± SEM are given; n=4-6; M month; 
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4.7 Changes in the levels of tau in three- and six-month old APP/PS1 mice 
In the APP/PS1 model the level of tau phosphorylation on serine 199 (S199), 
threonine 205 (T205), serine 396 (S396) and serine 404 (S404) in hippocampus was 
evaluated at three and six months of age. These particular phosphorylations were 
chosen based on previous experiments underlining their influence in AD pathology 
(Alonso et al. 2010, Spires-Jones et al. 2009). Quantification on western blots 
showed a significant (p˂0.05) increase in levels of phosphorylation in tau 
phosphoepitopes S199, T205 and S404 comparing APP/PS1 with their WT 
littermates at three months of age. By the age of six months a significant increase 
(p˂0.05 for S199, T205; p˂0.01 for S396, S404) of tau-phosphorylation was evident 
in all four phosphoepitopes (Figure 12 A-J). 
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Figure 12: Protein expression of Anti-Tau phosphorylated on serine 199 (pTau S199; three 
months A; six months B ), Anti-Tau phosphorylated on serine 396 (pTau S396; three months 
C; six months D), Anti-Tau phosphorylated on threonine 205 (pTau T205; three months E; 
six months F), Anti-Tau phosphorylated on serine 404 (pTau S404; three months G, six 
months H), and Tau total (three months I, six months J) in hippocampus of three and six 
months (M) old APP/PS1 mice. Tau-phosphoepitopes are normalized to their respective total 
unphosphorylated protein level and glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH). 
Western blot was performed according to standard protocol (see method section). Open 
columns: wild-type (WT) animals; solid columns: APP/PS1 mice. Means ± SEM are given; 
Student’s t-test $ p˂0.05, $$ p< 0.01; n=4-6; M month  
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4.8 APP/PS1 mice show loss of memory at six months of age 
Learning and recognition memory in APP/PS1 mice were tested using the Novel 
Object Recognition Test. If mice remember a familiar object, they explored before, 
they tend to prefer to explore a new object over the old object, shown in the graph as 
exploratory preference. A strict cut off at 0.15 was set (values below mean loss of 
memory). WT mice at three and six months of age as well as APP/PS1 at three 
months of age did spent significantly more time at the new object. At the age of six 
months APP/PS1 mice did not show discrimination between old and new object 
(˂0.05). Comparing the two genotypes of both age groups in general, APP/PS1 mice 
showed a lower exploratory preference than their WT littermates (Figure 13). 
 
Figure 13: Exploratory preference of APP/PS1 mice compared with wild-type (WT) 
littermates using Novel Object Recognition Test (performed as described in method section). 
Open columns: wild-type animals; solid columns: APP/PS1 mice. Means ± SEM are given; 
Tukey's post-hoc test *p˂0.05; n= 7-12; M month  
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5 Discussion  
The current thesis demonstrates that the development of familial Alzheimer disease 
in the APP/PS1 mouse model was associated with glucose intolerance and 
alterations in hippocampal insulin signalling. 
APP/PS1 double-transgenic mice (up to six months old) characterized by a significant 
overexpression of APP/PS1 in the hippocampus were used as model of human AD 
pathology. As published previously (Jankowsky et al. 2004, Pimplikar et al. 2010, 
Zhang et al. 2012), six-month old APP/PS1 mice showed increased soluble Aβ 
production and the presence of Aβ aggregates compared with WT age-matched 
controls (Figure 3). 
5.1 Is glucose intolerance partly responsible for cognitive loss in APP/PS1 
mice? 
The results from the IP-GTT show a tendency towards glucose intolerance in 
APP/PS1 mice aged three months. Sustained elevated glucose levels after six 
months failed to decrease to baseline levels until the end of study compared to age-
matched WT mice suggesting the development of glucose intolerance (Figure 6). In 
agreement with these results, Jimenez-Palomares et al. (2012) described that 
glucose tolerance was not impaired in 5-7-week old APP/PS1 mice, whereas 
Hiltunen et al. (2012) demonstrated significant alterations in glucose tolerance in 
female seven-month old APP/PS1 mice. 
The results from the Novel Object Recognition Test and the IP-GTT in APP/PS1 mice 
indicate a possible association between impaired glucose metabolism and loss of 
memory. Although not significant at three months of age, elevated glucose levels 
might be associated with a reduction in exploratory preference for the new object in 
APP/PS1 mice compared to control. At the age of six months glucose intolerance 
was significant (p<0.05) and accompanied by a clear decline (p<0.05) in memory 
function of APP/PS1 mice compared to the control group (Figure 13). Previous 
studies correspond to the above mentioned relationship between impaired glucose 
tolerance, T2DM and cognitive function. Awad et al. (2004) suggested that cognitive 
decline in T2DM patients may be associated with increased glucose levels or insulin 
resistance. Also prediabetic individuals having elevated glucose levels but not 
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reaching criteria for T2DM showed impaired cognitive function even while fasting. 
Cognitive function in these prediabetic patients was improved by enhancing glucose 
tolerance. Nevertheless it has been previously shown that cognitive deficits become 
irreversible in patients with fully developed T2DM (Greenwood 2003). Sadowksi et al. 
(2004) compared spatial memory tests, regional glucose metabolism, Aβ deposition, 
and neuronal loss in APP/PS1 with single mutated PS1 mice and WT littermates. At 
eight months, APP/PS1 mice developed selective decline in spatial memory, which 
was significantly worse at 22 months and accompanied by reduced hippocampal 
glucose utilization and a >35% decrease in neurons in the CA1 region of the 
hippocampus. PS1 mice showed a similar degree of neuronal loss in CA1 but only 
minimal memory deficit and no impairment of glucose utilization compared to the WT 
group. Moreover in 22-month old APP/PS1 mice substantially elevated Aβ levels 
have been demonstrated, which increased from 2.5±0.4% (8 months) to 17.4±4.6% 
(22 months) (Sadowski et al. 2004). 
The relationship of impaired glucose metabolism and cognitive decline can be partly  
explained by glucose being the exclusive energy source in the brain. Memorial tests 
performed on rats monitored using imaging techniques suggest that the 
hippocampus requires extraordinary amounts of glucose (Greenwood 2003). Memory 
loss in older rats might thus be partly explained by insufficient supply of glucose 
during the performance of the memory-demanding task. Greenwood (2003) 
concluded that diet has an influence on memory function. Prevention of chronic 
metabolic diseases like T2DM might consequently be a possibility to avoid impaired 
cognitive function in elderly people. 
5.2 Potential causes and consequences of impaired insulin signalling in 
APP/PS1 mice 
According to Hoyer (2004) and De La Monte (2012) AD could be characterized by 
impairment in the brain's capacity to utilize glucose and to respond to insulin and IGF 
stimulation. The binding of insulin to the IR could influence synaptic plasticity, 
memory formation and insulin signalling through IRS mediated cell growth, survival 
energy metabolism and cholinergic gene expression (De La Monte and Wands 2008). 
Impairments in brain insulin/IGF signalling and IRS 1 and 2, downstream the IR could 
lead to increased expression of APP, accumulation of Aβ and cognitive impairment. 
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In agreement with this hypothesis the small but significant reduction in hippocampal 
IR and IRS 2 transcripts in APP/PS1 mice at three months compared to WT animals 
described in this thesis might have influence on the cognitive decline in APP/PS1 
mice (Figure 8). Also Soeda et al. (2010) demonstrated that neuronal apoptosis and 
degraded memory function was caused by Akt-mediated IR/IGF 1 receptor-signalling 
pathway. Plaschke et al. (2010) induced an insulin-resistant brain state by 
intracerebroventricular administration of streptozotocin in AβPP Tg2576 mice and 
investigated the effects on behaviour and GSK α/GSK β content as well as the 
formation of Aβ plaques and tau protein. Transgenic mice treated with streptozotocin 
showed increased mortality, reduced spatial cognition, increased cerebral 
aggregated tau protein and Aβ formation. Consequently an insulin-resistant brain 
state may worsen AD-like pathologies such as the formation of AD hallmarks like 
neuritic plaques. Also ATP synthesis might be regulated by insulin via the Pi3K/Akt 
signalling pathway and might be important for axon regeneration (Huang et al. 2005). 
Impairment of insulin signalling as detected in the APP/PS1 mice might influence 
neuronal energy metabolism, e. g. by damaging ATP-synthesis due to inhibition of 
the Pi3K/Akt signalling pathway resulting in neuronal apoptosis and thus eventually 
contributing to AD pathology. 
Salkovic-Petrisic et al. (2014) investigated the effects of D-galactose administration in 
a streptozotocin-induced rat model of sporadic AD as an alternative source of energy 
transported into the brain by insulin-independent GLUT3 transporter where it is 
metabolized to glucose via the Leloir pathway. Daily oral galactose (100 to 300 
mg/kg/day) treatment started immediately after the streptozotocin administration, 
prevented development of the streptozotocin-induced cognitive deficits. The 
beneficial effect was independent of the galactose dose and the age of the rat. 
Consequently administration of oral galactose might be linked with beneficial effects 
on learning and memory ability and improvement of cognitive deficits associated with 
glucose hypometabolism in AD. Insulin-deficient diabetes may be associated with 
cerebral AD characteristic amyloidosis (Sato et al. 2013). In a streptozotocin-induced 
diabetic APP/PS1 mouse model, the diabetic condition promoted the processing of 
APP leading to the formation of Aβ-generated neuritic plaques, the formation of NFT, 
and spatial memory deficits (Wang et al. 2010). According to Haataja et al. (2008) 
patients suffering from T2DM show islet amyloid polypeptide deposition in pancreatic 
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cells which could be quite similar to those found in the brain of AD patients. 
Nevertheless further research is required to clarify whether islet amyloid polypeptide 
deposition in pancreatic cells can be directly compared to those detected in the brain 
of AD patients. Cerebral glucose metabolism, insulin and IGF resistance and 
deficiency in the brain should be included in an overarching hypothesis which might 
help to develop more realistic diagnostic and therapeutic approaches to AD.  
The effect of reduced levels of IRS 2 transcripts on cerebral insulin resistance in the 
hippocampus remains unknown. However, Kubota et al. (2000) described that IRS 2-
deficient mice developed liver insulin resistance and T2DM. 
5.3 Aβ peptide toxicity and hippocampal insulin resistance – is there a 
positive feedback loop? 
Recent experiments support the theory that Aβ peptide toxicity could be partly 
responsible for development of insulin resistance (Townsend et al. 2007). The 
authors addressed the question how Aβ impairs synaptic plasticity. Mouse 
hippocampal neurons treated with soluble human Aβ showed inhibition of three major 
kinases including Akt important for LTP. Furthermore the authors described soluble 
Aβ to bind at the IR and to impair its autophosphorylation process leading to the 
inactivation of Akt and other kinases necessary for functional LTP. A positive 
feedback loop of progressive neurodegeneration might be developed, because 
insulin resistance results in Aβ accumulation, whereas Aβ fibril toxicity promotes 
brain insulin resistance. This could partly explain the failure of anti-APP-Aβ 
monotherapy to show significant benefits in clinical trials, due to the fact that brain 
insulin resistance and deficiency might also have to be therapeutically targeted to 
prevent AD progression. Townsend et al. (2007) described that an IR antagonist 
could mimic the inhibitory effect of Aβ on these kinases. Therefore, targeting brain 
insulin/IGF resistance and deficiency, including the use of intranasal insulin delivery, 
incretins and insulin sensitizer agents could be of clinical value. Nevertheless lifestyle 
changes to modify risk for developing mild cognitive impairment or AD must be 
emphasized. Consequently, a multimodal rather than unimodal diagnostic and 
therapeutic strategy could be successful in improving therapeutic strategies against 
AD (De La Monte 2012).  
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5.4 Does insulin-like growth factor 2 cause metabolic alterations in APP/PS1 
mice? 
A significant increase in IGF 2 transcripts became evident at the age of six months 
accompanied by the development of glucose intolerance in APP/PS1 mice (Figure 8). 
It has previously been described that single mutant IGF 2 animals showed impaired 
glucose and insulin tolerance even exacerbated in triple APP/PS1/IGF2 mice 
(Hiltunen et al. 2012). Consequently the increase in IGF 2 at six months of age 
suggests IGF 2 signalling to be involved in causing the metabolic alterations in 
APP/PS1 mice. However, a recent study suggested that intracerebroventricular 
infusion of IGF 2 would enhance hippocampal function by improving memory 
consolidation, activating adult neurogenesis and stimulating cholinergic marker 
expression in APP/PS1 mice (Mellott et al. 2014).  
The present study could not demonstrate changes in IGF 1 in the APP/PS1 mouse 
model as potential regulator of development of cognitive function and aging 
processes as described by Doi et al. (2015).  
5.5 Hyperinsulinaemia and development of Alzheimer disease in APP/PS1 
mice 
Both clinical and experimental data indicate a link of chronic hyperinsulinaemia to 
cognitive impairment and neurodegeneration with impaired Aβ processing. However, 
during this study a significant increase in serum insulin levels was not detected 
(Figure 7). Bingham et al. (2002) investigated whether peripheral basal insulin levels 
influence glucose uptake in the brain. Somatostatin was applied to 8 male healthy 
volunteers to inhibit endogenous insulin secretion. One group was infused with 0.3 
mU × kg−1 × min−1 insulin to simulate basal insulin levels. Saline infusion was used as 
placebo. Volunteers were examined twice in a random order using 18-
fluorodeoxyglucose and positron emission tomography. The authors concluded that 
elevated basal insulin levels resulted in an approximately 15% increase in glucose 
uptake in the brain that could be clinically relevant (Bingham et al. 2002). Metabolic 
changes, such as impaired insulin and IGF 1 signalling could lead to down-regulation 
of GLUT1 and GLUT3 in the brain resulting in insufficient glucose supply causing 
neuronal loss and cognitive dysfunction (Moreira et al. 2009, Liu et al. 2008). 
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However, other studies failed to show a significant influence of basal insulin levels on 
cerebral glucose uptake (Seaquist et al. 2001). 
5.6 Insulin-degrading enzyme and the phenomenon of eclipsed distribution  
IDE is important for degradation of both insulin and Aβ. Insulin resistance results in 
impaired Aβ degradation and formation of neurotoxic Aβ plaques contributing to the 
occurrence of AD (Rhein and Eckert 2007). However, no changes in expression of 
IDE were found in APP/PS1 mice compared with age-matched controls (Figure 9) 
contradicting previous published data (Ho et al. 2004, Moreira et al. 2013). Although 
no significant changes of the expression of IDE were found in the APP/PS1 mice, 
insulin resistance could lead to the formation of Aβ deposits because mainly insulin is 
degraded by IDE, impairing the physiological clearance of Aβ through the same 
molecule. Consequently APP/PS1 mice may not be able to control impaired insulin 
signalling in hippocampal neurons by increasing expression of IDE in the brain. In 
addition, the dominant isoform of IDE is mainly localized in the cytosol and only 
present in minute amounts in the mitochondria where it interacts with the process of 
Aβ degradation. The phenomenon of eclipsed distribution could be responsible for 
the absence of changes in protein expression of IDE. According to Regev-Rudzki and 
Pines (2007) the detection of mitochondrial changes in insulin-degrading enzyme by 
standard biochemical and visualization methods could be masked by the presence of 
the dominant isoprotein in the cytosol. Consequently changes in minute amounts of 
the protein can hardly be found.  
5.7 Tau phosphorylation and implication of different tau kinases in the 
APP/PS1 mouse model  
Throughout the phosphorylation of the IR two major signalling pathways are triggered: 
the extracellular Ras/Raf-1 signalling pathway and the previously described GSK3β 
signalling pathway with the upstream molecule Akt. 
Ras/Raf-1 signalling pathway was described to interact in the regulation of 
expression and post-translational modification of the APP and tau protein. Increased 
expression of p21ras was accompanied by formation of NFT and Aβ plaques 
(Gärtner et al. 1999). 
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GSK3β, inactivated by phosphorylation on serine 9, is mostly found in the cytosol. As 
previously mentioned dephosphorylated active GSK3β appearing mostly in 
mitochondria and nuclei is involved in the process of tau phosphorylation and Aβ 
accumulation. In the current work a significant increase in hippocampal 
phosphorylation of the tau phosphoepitopes p-Tau (S199), p-Tau (T205), p-Tau 
(S396) and p-Tau (S404) was detected (Figure 12). The protein expression of 
phosphorylated form of GSK3β remained unchanged, indicating an alternative 
pathway of tau phosphorylation in this APP/PS1 mouse model (Figure 11). Ahmed 
and Sharma (2011) focused on the hyperactivation of CDK5 as a common pathway 
triggering pathology in AD and T2DM.  
In APP/PS1 mice three and six months old pCDK5 Y15 was increased (Figure 10). 
The correlation between elevated levels of phosphorylated tau and CDK5 suggests 
that in the APP/PS1 mice CDK5 is active and might co-regulate tau phosphorylation. 
To investigate whether CDK5 is a key regulator of tau phosphorylation in APP/PS1 
mice, expression of other tau kinases such as further mitogen-activated protein 
kinase family members (e.g. kinases 1 and 2) should be investigated. However, 
previous studies emphasize the role of tau kinase CDK5. According to Shukla et al. 
(2012) neurofilaments and tau are both hyperphosphorylated by CDK5 and an 
integral part of the paired helical filament forming NFT. They suggested that CDK5 
plays a crucial role in neuronal development. Neuronal activators of CDK5 are p35 
and p39. Stress induced calpain cleavage of p35 and p39 results in truncated 
products as p25 and p29. Association of CDK5 with p25 is supposed to cause 
hyperphosphorylation of multiple substrates of CDK5 like APP, tau and 
neurofilaments, resulting in AD like pathology. Moreover, recent data have shown 
increased levels of p25, Aβ, hyperactivity of CDK5, phosphorylated tau and 
neurofilament in human AD brains (Shukla et al. 2012). 
Also Jaypalan and Natarajan (2013) who investigated the tertiary structure of tau and 
the role of CDK5 and GSK3ß in abnormal tau hyperphosphorylation concluded that 
CDK5 seemed to be more relevant in tau hyperphosphorylation than GSK3ß. Hence 
CDK5 as a therapeutic target could be particularly promising in avoiding NFT 
formation. Nevertheless, more research is needed to clarify the complicated 
interaction of phosphorylations and co-activators that lead to CDK 5 activation.  
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However, tau phosphorylation in general seems to be a multifactorial process. For 
example, the most important tau phosphatase, also involved in tau phosphorylation, 
is protein phosphatase 2A (PP2A). AD-induced decrease of PP2A also contributes to 
tau hyperphosphorylation due to impaired tau dephosphorylation (Iqbal and Grundke-
Iqbal 2005). 
Tau phosphorylation is also regulated by posttranslational O-linked N-
acetylglucosaminylation (O-GlcNAcylation). Inhibition of O-GlcNAcylation as a result 
of decreased cerebral glucose levels resulted in increased hyperphosphorylation of 
tau in AD brains (Liu et al 2009). Consequently, impairment of brain glucose 
metabolism prior to development of AD could be a cause for developing 
neurodegeneration and restoring brain O-GlcNAcylation could be an option for the 
treatment of AD. 
 
Figure 14: Key molecular pathways focussing on the formation of neurofibrillary tangles (NFT).  
Aβ amyloid β; AD Alzheimer disease; IDE insulin-degrading enzyme; GSK3β glycogen synthase kinase 
3β; INS insulin; IR insulin receptor; IRS insulin receptor substrate; PP2A protein phosphatase 2A; 
CDK5 cyclin-dependant kinase 5 
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5.8 Potential Alzheimer disease therapies targeting tau phosphorylation 
Currently, various therapeutic approaches in the treatment of AD are focused on 
targeting tau hyperphosphorylation. Hyperphosphorylated tau, representing the major 
protein of NFT in AD is most probably the result of an imbalance of tau kinase and 
phosphatase activities in the affected neurons. Thus, inhibition of tau 
hyperphosphorylation appears a promising therapeutic approach in AD. As PPA2 is a 
major regulator of tau phosphorylation that showed reduced enzymatic activity in AD 
(Gong et al 2000), maintaining or restoring PP2A activity may stop, prevent or even 
counteract further progress of the disease, e.g. by reducing cleavage and 
translocation of I2(PP2A), an endogenous inhibitor of PP2A. This could be achieved 
by direct inhibition of I2(PP2A) or by inhibition of asparaginyl endopeptidase that 
causes cleavage of the inhibitor (Tanimukai et al. 2005, Iqbal et al. 2014). 
Chronic inhibition of GSK3β by lithium chloride significantly decreased levels of 
hyperphosphorylated tau. Considering the potential toxicity of lithium Nunes et al. 
(2013) studied the effect of lithium at a low-dose of 300 µg. The drug was 
administered to AD patients once daily for 15 months. The lithium-treated patients 
maintained the performance in the mini-mental state examination test in contrast to 
the control group with significant differences three months after the onset of 
treatment and progressively increasing thereafter. Accordingly, this clinical study 
shows benefits of low-dose lithium therapy by preventing ongoing cognitive loss 
associated with AD.  
Another study investigated the disease-modifying properties of long-term lithium 
treatment for amnestic and mild cognitive performance in 45 AD patients. The 
treatment group (n=24) titrated to target lithium serum levels of 0.25–0.5 mM 
exhibited significantly less levels of phosphorylated tau in the cerebrospinal fluid and 
improved performance on the cognitive subscale of the AD Assessment Scale and 
attention tasks. In healthy volunteers this concentration range of lithium caused a  
50 % reduction in GSK3β activity in leukocytes. Overall tolerability of lithium was 
good during the study with an adherence rate of 91 % (Forlenza et al. 2011).  
In a clinical phase II study with the tau aggregation inhibitor methylene blue only a 
low dose (60 mg) showed improvement of memory function, whereas the higher dose 
(100 mg) failed to show any benefits (Iqbal et al 2014). 
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Active and passive immunotherapy for tau significantly reduced density of NFT as 
well as improved cognitive function in transgenic mouse models. Moreover, a tau-
immunization based vaccine is currently tested in a phase I clinical trial investigating 
inhibition of the spread of the tau pathologies to the extracellular space. This clinical 
approach seems promising considering that extracellular tau is correlated with 
cognitive decline (Iqbal et al 2014). 
5.9 Methodological discussion 
The thesis combined various in vitro (ELISA, RT-PCR and WB) and in vivo (IP-GTT 
and the Novel Object Recognition Test) methods to investigate a potential 
relationship between AD and diabetes.  
RT-PCR identified changes in mRNA expression, whereas WB demonstrated 
changes in protein expression. ELISA detected potential changes in serum insulin 
levels.  
RT-PCR investigated changes related to insulin signalling in the hippocampus of 
APP/PS1 mice compared to WT littermates. RT-PCR was chosen as a solid and well 
established method. However, due to time limitation of the project it was needed to 
focus on target molecules of highest significance such as CDK5 and GSK3β. 
Whenever possible both RT-PCR and WB were used in order to compare mRNA 
expression with the resulting protein expression.  
Serum insulin-ELISA was chosen as a complementary method to the IP-GTT in order 
to demonstrate a possible relationship between potential disturbances in glucose 
levels with alterations in serum insulin levels. Furthermore early development of 
insulin resistance in the APP/PS1 mice could have been detected by serum insulin-
ELISA.  
The IP-GTT and Novel Object Recognition Test were used as in vivo methods. The 
IP-GTT was performed in order to demonstrate whether APP/PS1 mice develop a 
diabetic phenotype or not. Glucose intolerance often is the first symptom before 
developing insulin resistance resulting in diabetes. Consequently focusing on glucose 
intolerance made it possible to detect early changes in the glucose metabolism of the 
mice before the development of the full diabetic phenotype and to examine whether 
even at that early stage these changes could be related to the development of AD.  
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Cognitive decline is a key symptom of AD and thus detected in  APP/PS1 mice could 
give valuable information about the age of onset of AD. The Novel Object 
Recognition Test was chosen on the basis of being relatively easy to establish in the 
laboratory and being successful in detecting memory changes in mice in previous 
studies (Barroso et al. 2013). 
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6 Conclusions 
The present results demonstrate that the development of cognitive decline and tau 
hyperphosphorylation in an APP/PS1 mouse model of FAD was accompanied by an 
early downregulation of glucose and insulin signalling pathways (Figure 15).  
Figure 15: Summary of key results presented in this thesis. AD Alzheimer disease; IR insulin receptor; 
IRS insulin receptor substrate; CDK5 cyclin-dependant kinase 5; IGF 2 insulin-like growth factor 2; 
T2DM type-2 diabetes mellitus, NFT neurofibrillary tangles 
A small but significant reduction in transcripts of IR and IRS 2 in three-month old 
APP/PS1 mice (p<0,05) was detected using RT-PCR. Perturbation in glucose 
metabolism (p<0,05) in six-month old APP/PS1 mice were accompanied by 
significant cognitive deficits (p<0,05) demonstrated using the Novel Object 
Recognition Test. A significant increase in IGF 2 transcripts (p<0,05) was associated 
with the metabolic alterations affecting APP/PS1 mice. 
Lack of changes in IDE were possibly explained by the phenomenon of eclipsed 
distribution. It has been emphasized that AD and T2DM share several pathologic 
features and a possible link has been suggested showing a significant increase in 
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protein expression of pCDK5 (Y15) phosphorylation in APP/PS1 mice at three 
(p<0.05) and six months (p<0.01) of age accompanied by elevated protein 
expression of tau phosphoepitopes S199, T205, S396 and S404 (three months: 
p<0,05 for S199, T205, S404; six months: p<0.05 for S199, T205; p<0,01 for S396, 
S404). Thus CDK5 might be responsible for tau phosphorylation and formation of 
NFT in hippocampi of APP/PS1 mice thereby contributing to AD pathology. However, 
the implication of other tau kinases is still open and should be investigated in further 
studies. 
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7 Summary of work 
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Familial Alzheimer disease in the APP/PS1 mouse model is associated with 
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und  
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Dezember 2015 
The current thesis demonstrates that the development of familial Alzheimer disease 
in the APP/PS1 mouse model was associated with glucose intolerance and 
alterations in hippocampal insulin signalling. 
Compared to wild-type animals, a reduction in hippocampal insulin receptor and 
insulin-receptor substrate 2 transcripts (p<0.05) in APP/PS1 mice three-months old 
as well as an increase in insulin-like growth factor 2 transcripts (p<0.05) after six 
months was detected using real-time polymerase chain reaction. The alterations in 
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hippocampal insulin signalling were accompanied by perturbation of glucose 
metabolism analysed by intraperitoneal glucose tolerance test. Even APP/PS1 mice 
at three months of age showed a tendency towards impaired glucose metabolism, 
nevertheless, levels of glucose gradually decreased to the physiological baseline 
level at the end of the observation period. At the age of six months peak levels of 
glucose of APP/PS1 mice remained significantly increased (p<0.05) above 
physiological levels over the whole study period, demonstrating development of 
glucose intolerance. 
Hiltunen et al. (2012) described that single mutant insulin-like growth factor 2 animals 
showed impaired glucose and insulin tolerance even exacerbated in triple 
APP/PS1/IGF2 mice. Consequently the increase in insulin-like growth factor 2 
signalling may be involved in metabolic alterations in APP/PS1 mice. Changes in 
insulin-like growth factor 1 as potential regulator of development of cognitive function 
and aging processes could not be found in this APP/PS1 mouse model.  
Learning and recognition memory in APP/PS1 mice was tested using the Novel 
Object Recognition Test. Cognitive decline became evident in APP/PS1 mice at six 
months of age because mice were not able to discriminate between old and new 
objects (p<0.05). 
Degradation of both insulin and amyloid β is mediated through insulin-degrading 
enzyme. However, insulin-degrading enzyme expression in APP/PS1 mice was not 
different from wild-type littermates. Possibly, the dominant isoform of insulin-
degrading enzyme that is mainly localized in the cytosol masked changes in insulin-
degrading enzyme levels in mitochondria where it interacts with amyloid β 
degradation.  
Neurofibrillary tangles are a hallmark of Alzheimer disease. In the current work 
changes in hippocampal phosphorylation of the tau phosphoepitopes p-Tau (serine 
199), p-Tau (threonine 205), p-Tau (serine 396) and p-Tau (serine 404) were 
investigated using Western blot. The expression of the three phosphoepitopes was 
increased significantly at either age (three months: p˂0,05 for serine 199, threonine 
205, serine 404; six months: p<0.05 for serine 199, threonine 205; p<0,01 for serine 
396, serine 404) . 
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Interestingly, protein expression of the phosphorylated form of glycogen synthase 
kinase 3β, previously described as major tau kinase, remained unchanged indicating 
an alternative pathway of tau phosphorylation in the APP/PS1 mouse model of 
familial Alzheimer disease. Previous studies focused on hyperactivation of cyclin-
dependant kinase 5 as a possible link triggering pathology in Alzheimer disease and 
type-2 diabetes mellitus.  
The current results demonstrate an increase in cyclin-dependant kinase 5 
phosphorylation in APP/PS1 mice aged three (p<0.05) and six months (p<0.01). The 
correlation between elevated levels of phosphorylated tau and cyclin-dependant 
kinase 5 suggests that cyclin-dependant kinase 5 is active and might be a regulator 
of tau phosphorylation in APP/PS1 mice.  
In general, this work corroborates common pathologic features in Alzheimer disease 
and diabetes mellitus. A significant cognitive decline in APP/PS1 mice was 
associated with changes in early gene expression of insulin-related molecules and 
perturbations in glucose metabolism. Cyclin-dependant kinase 5 is considered to co-
regulate tau phosphorylation in APP/PS1 mice, and to be part of a pathway 
contributing to pathology in Alzheimer disease. 
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